Our clinical operations teams drove impressive enrollment numbers this year based on strong interest from patients and investigators,” stated Lisa Ricciardi, Cognition’s president and CEO. “During the ...
Researchers say the study indicates the ability to bring the power of AI and patient-reported outcomes directly into the clinic seamlessly, affordably, and at scale.
5don MSN
Zero-cost, AI-driven digital detection identifies Alzheimer's without additional clinician time
Few primary care practices are designed for the timely detection of Alzheimer's disease and related dementias. The limited ...
News Medical on MSN
AI-Driven Tool Identifies Alzheimer's Without Additional Clinical Time
Discover how digital detection of dementia enhances early diagnosis in primary care without extra clinician time or costs.
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi (lecanemab) has been ...
Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aß) monoclonal antibody “LEQEMBI ® ” (generic name: lecanemab) has been approved for once every four weeks ...
Nervous system issues often show early signs before a full diagnosis. Doctors highlight five key red flags: resting tremor, ...
The Brighterside of News on MSN
New AI-powered screening method helps primary care doctors quickly identify dementia
Primary care clinics carry a tough burden. You walk in with concerns about blood pressure, pain or medication questions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback